Next Article in Journal

The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18–59 Years and over 60 Years Based on Two Randomized Controlled Trials in China

Next Article in Special Issue

Safety and Immunogenicity of the Convacell^® Recombinant N Protein COVID-19 Vaccine

Previous Article in Journal

COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases

Previous Article in Special Issue

Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901-Beta SARS-CoV-2 Vaccine in Adults: A Phase I, Prospective, Randomized, Open-Labeled Study

You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.

Search for Articles:

Title / Keyword

Author / Affiliation / Email

Journal

Article Type

Advanced Search

Section

Special Issue

Volume

Issue

Number

Page

Logical OperatorOperator

Search Text

Search Type

Submit to this Journal Review for this Journal Propose a Special Issue

Article Menu

Share Help Cite Discuss in SciProfiles

Open AccessFeature PaperArticle

Article Versions Notes

Vaccines 2023, 11(12), 1814; https://doi.org/10.3390/vaccines11121814

Action	Date	Notes	Link
article html file updated	12 September 2025 09:51 CEST	Update	https://www.mdpi.com/2076-393X/11/12/1814/html
article html file updated	23 August 2025 01:57 CEST	Update	-
article html file updated	4 December 2023 08:18 CET	Original file	-
article supplementary file uploaded.	4 December 2023 08:17 CET	-	https://www.mdpi.com/2076-393X/11/12/1814#supplementary
article pdf uploaded.	4 December 2023 08:17 CET	Version of Record	https://www.mdpi.com/2076-393X/11/12/1814/pdf
article xml uploaded.	4 December 2023 08:17 CET	Update	https://www.mdpi.com/2076-393X/11/12/1814/xml
article xml file uploaded	4 December 2023 08:17 CET	Original file	-

Back to TopTop